

## **Tanvex BioPharma USA Enters License and Supply Agreement with Invagen Pharmaceuticals, a Cipla Group Company for the Commercialization of NYPOZI in the United States**

June 30, 2025

Tanvex BioPharma USA, Inc. ("**Tanvex**"), a subsidiary of Tanvex BioPharma, Inc. and a contract development and manufacturing organization (CDMO) specializing in biologics under the brand Bora Biologics ("**Bora Biologics**"), is excited to announce a strategic license and supply agreement with Invagen Pharmaceuticals, Inc., a wholly owned subsidiary of Cipla Limited in United States (hereinafter referred as 'Cipla'). This partnership will facilitate the commercialization of NYPOZI™ (filgrastim-txid), a biosimilar to Neupogen®, in the United States.

Under the terms of this agreement, Cipla will be responsible for the marketing and sales of NYPOZI™ to healthcare providers and patients throughout the U.S. market. Tanvex BioPharma will benefit from milestone payments, supply payments, and a share of the profits generated from Invagen's sales of NYPOZI™. The collaboration underscores Tanvex's commitment to expanding access to high-quality biosimilars and reinforces its position in the competitive biologics landscape.

"We are thrilled to partner with Cipla to bring NYPOZI™ to the U.S. market," said Stephen Lam, CEO of Tanvex. "This agreement not only validates the value of our development capabilities, but also allows us to focus our efforts and resources on scaling our CDMO platform to meet the rising global demand for high-quality biologics manufacturing while unlocking the value of our biosimilar assets."

The agreement reflects Tanvex's dedication to collaboration and innovation in the biopharmaceutical sector. While specific financial details remain confidential, the partnership represents a significant step forward in delivering life-saving therapies to patients across the United States. The companies are actively working on launch plans and expect to introduce NYPOZI™ in the United States in the coming months.

1.

### **About NYPOZI™**

[SEE FULL PRESCRIBING INFORMATION FOR NYPOZI™](#) for complete information on indications and usage, dosage and administration, contraindications, warnings and precautions, and adverse reactions.

For subcutaneous or intravenous use, NYPOZI™ is a leukocyte growth factor indicated to:

- Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever
- Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia
- Reduce the duration of neutropenia and neutropenia-related clinical sequelae, e.g., febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT)
- Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis
- Reduce the incidence and duration of sequelae of severe neutropenia (e.g., fever, infections, oropharyngeal ulcers) in symptomatic patients with congenital neutropenia, cyclic neutropenia, or idiopathic neutropenia
- Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome)

Nypozi is also approved and available in Canada. [SEE PRODUCT MONOGRAPH FOR NYPOZI IN CANADA](#) for information on indications and usage, dosage and administration, contraindications, warnings and precautions, and adverse reactions.

### **About Tanvex and Bora Biologics**

Tanvex BioPharma, Inc. (TWSE: 6541), was founded in 2011 with a mission to revolutionize the healthcare industry by making biologics more affordable and accessible to patients. Over the years, Tanvex has honed its expertise in biologics development and manufacturing, culminating in the successful commercialization of our first product. With another Biological License Application (BLA) pending U.S. FDA approval, Tanvex's journey is characterized by an unwavering commitment to excellence, innovation, and a passion for improving patient care.

Tanvex's commitment to advancing healthcare has led to the expansion of its capabilities as a biologics CDMO under the name Bora Biologics. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics provides agile, comprehensive end-to-end solutions that enhance time and cost efficiencies for biopharma companies worldwide. By leveraging global CDMO capabilities, a state-of-the-art, FDA-registered facility in the U.S., and deep expertise in biologics development and manufacturing, Bora Biologics ensures efficient and effective pathways to market for its clients.

**About Invagen Pharmaceuticals, Inc.**

Invagen Pharmaceuticals, Inc., a subsidiary of Cipla, provides high-quality pharmaceutical products that improve patient health and well-being. With a robust portfolio of generic and specialty medications, Invagen is committed to making healthcare more accessible.

**Websites**

<https://tanvexusa.com>

<https://borabiologics.com>

**Media Contact**

[media@borabiologics-us.com](mailto:media@borabiologics-us.com)

**CDMO Inquiries**

[bd@borabiologics-us.com](mailto:bd@borabiologics-us.com)

**About Cipla:**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. For nearly nine decades, making a difference to patients has inspired every aspect of Cipla's work. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. Cipla is a respiratory leader, ranking #2 in inhaler sales globally and in the top 3 for US generic respiratory sales (IQVIA TRx data as of February 2025)\*. For more information about Cipla and its commitment to respiratory health, please visit Cipla's USA website at [www.ciplausa.com](http://www.ciplausa.com).